Page 222 - Read Online

Berge et al. Clinical outcomes of direct-acting antivirals

morbidity and mortality in patients with hepatitis C virus. Clin of evidence of an effect of direct-acting antivirals on the recurrence of
Gastroenterol Hepatol 2010;8:280-8. hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol
11. van der Meer AJ, Berenguer M. Reversion of disease manifestations 2016;65:734-40.
after HCV eradication. J Hepatol 2016;65:S95-108. 17. Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M,
12. Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular
for chronic hepatitis C virus infection with cirrhosis. World J Hepatol carcinoma: a review. J Hepatocell Carcinoma 2016;3:41-53.
2015;7:1133-41. 18. Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related
13. Horsley-Silva JL, Vargas HE. New therapies for hepatitis C virus hepatocellular carcinoma in the era of new generation antivirals. BMC
infection. Gastroenterol Hepatol (N Y) 2017;13:22-31. Med 2017;15:52.
14. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, 19. Yoon JC, Yang CM, Song Y, Lee JM. Natural killer cells in hepatitis
Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti C: current progress. World J Gastroenterol 2016;22:1449-60.
S. Early occurrence and recurrence of hepatocellular carcinoma in 20. Tatsumi T, Takehara T. Impact of natural killer cells on
HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol chronic hepatitis C and hepatocellular carcinoma. Hepatol Res
2016;65:727-33. 2016;46:416-22.
15. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, 21. Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer
Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns R, Stern R, Chromy D, Stättermayer AF, Reiberger T, Beinhardt
X, Bruix J. Unexpected high rate of early tumor recurrence in patients S, Sieghart W, Trauner M, Hofer H, Ferlitsch A, Ferenci P, Peck-
with HCV-related HCC undergoing interferon-free therapy. J Hepatol Radosavljevic M. Sustained virologic response to interferon-free
2016;65:719-26. therapies ameliorates HCV-induced portal hypertension. J Hepatol
16. ANRS collaborative study group on hepatocellular carcinoma. Lack 2016;65:692-9.

214 Hepatoma Research ¦ Volume 3 ¦ September 27, 2017